SNY

Sanofi - ADR

42.85

USD

-0.30

-0.71%

Sep 09, 15:59 UTC -4

Closed

After-Market

43.11

+0.26

+0.62%

Sanofi - ADR Profile

About

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Info & Links

CEO

Paul Hudson

Headquarters

46 AVENUE DE LA GRANDE ARMEE
PARIS, I0 75017, FRANCE

Auditor

PricewaterhouseCoopers

Share holders

Employees

74,846

Sanofi - ADR Statistics

Valuation Measures

Market Capitalization²

103.31B

Enterprise Value

121.12B

Enterprise Value/EBITDA(ttm)

11.66

Price to Earnings Ratio(ttm)

9.03

Price to Sales(ttm)

2.01

Price to Book(mrq)

1.33

Price to Cash(ytd)

6.26

Profitability

Gross Margin(ttm)

72.73%

Operating Margin(ttm)

22.13%

Profit Margin(ttm)

8.05%

Return on Equity(ttm)

14.19%

Return on Invested Capital(ttm)

4.72%

Return on Assets(ttm)

7.95%

Income Statement

Revenue(ttm)

56.96B

Revenue Per Share(ttm)

Gross Profit(ttm)

41.45B

EBITDA(ttm)³

10.39B

Net Income Available to Common(ttm)

4.68B

Diluted EPS(ttm)

1.91

Share Statistics

Beta (5Y Monthly)

0.35

52-Week Change

-8.44%

S&P 500 52-Week Change

18.41%

S&P 500 Member

Stock Optionable

Yes

Total Shares Outstanding¹

Dividend Yield

3.99%

Float⁴

2.40B

% Held by Insiders

1.00%

% Held by Institutions

14.03%

Balance Sheet

Total Cash(mrq)

7.38B

Total Cash Per Share(mrq)

Total Debt(mrq)

25.20B

Total Debt/Equity(mrq)

31.15%

Current Ratio(mrq)

0.99%

Quick Ratio(mrq)

0.64%

Book Value Per Share(mrq)

33.31

Cash Flow

Operating Cash Flow Per Share(ytd)

2.26

Free Cash Flow(ytd)

4.38B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

SNY